SCHEMBL4476302

SCHEMBL4476302

CCc1cc(CC)c2c(C#N)c(C=CC(=O)Nc3cccnc3)n(C3CCc4ccccc43)c2n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.36
NPC1 O15118 8/20 0.36
MARK3 P27448 1/20 0.35
MARK4 Q96L34 1/20 0.35
ALDH1A1 P00352 6/20 0.35
KDM4E B2RXH2 5/20 0.35
SMN1; SMN2 Q16637 5/20 0.35
PKM P14618 2/20 0.35
HTR2A P28223 2/20 0.35
HTR2C P28335 2/20 0.35
CACNA1G O43497 1/20 0.34
CACNA1H O95180 1/20 0.34
CACNA1I Q9P0X4 1/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
HTT P42858 2/20 0.34
HPGD P15428 1/20 0.34
BLM P54132 1/20 0.34
NAMPT P43490 2/20 0.33
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4476297 1.00 RAB9A (0.36) RAB9ANPC1MARK3MARK4ALDH1A1
SCHEMBL4476927 0.92 KCNA5 (0.33) RAB9ANPC1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL4476919 0.92 KCNA5 (0.33) RAB9ANPC1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL4491021 0.86 RAB9A (0.38) RAB9ANPC1MARK3MARK4ALDH1A1
SCHEMBL4491015 0.86 RAB9A (0.38) RAB9ANPC1MARK3MARK4ALDH1A1
SCHEMBL4470416 0.85 CMA1 (0.35)
SCHEMBL4470424 0.85 CMA1 (0.35)
SCHEMBL4483328 0.85 RAB9A (0.36) RAB9ANPC1MARK3MARK4ALDH1A1
SCHEMBL4483320 0.85 RAB9A (0.36) RAB9ANPC1MARK3MARK4ALDH1A1
SCHEMBL4469817 0.83 RAB9A (0.39) RAB9ANPC1MARK3MARK4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582651-B2 Pyrrolopyridine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-01 US disclosed
US-20060167038-A1 Pyrrolopyridine derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-27 US disclosed
EP-1535922-A1 PYRROLOPYRIDINE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2005-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167038-A1 Pyrrolopyridine derivative and use thereof OPRD1, TRPV1, OPRM1 RAB9A 3079/4885NPC1 4441/4885MARK3 4316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.